Last reviewed · How we verify
SC-101
At a glance
| Generic name | SC-101 |
|---|---|
| Sponsor | Tianjin ConjuStar Biologics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease (PHASE1)
- SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers (PHASE2)
- Study SC-101 in Subjects With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC-101 CI brief — competitive landscape report
- SC-101 updates RSS · CI watch RSS
- Tianjin ConjuStar Biologics Co., Ltd. portfolio CI